Andrew lloyd: a driving force in patient-centered outcomes research.

Patient

1 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA 2 Wolters Kluwer Health ∣ Adis, Auckland, New Zealand.

Published: December 2008

Download full-text PDF

Source
http://dx.doi.org/10.2165/01312067-200801040-00007DOI Listing

Publication Analysis

Top Keywords

andrew lloyd
4
lloyd driving
4
driving force
4
force patient-centered
4
patient-centered outcomes
4
andrew
1
driving
1
force
1
patient-centered
1
outcomes
1

Similar Publications

Objectives: Papers reporting value sets typically only report the standard errors (SEs) around each estimated coefficient in value set models. This is important information but does not help those building cost effectiveness models, who need to know the uncertainty around the values of health states in order to conduct sensitivity analyses. This paper's aim is to demonstrate how SEs around HRQoL values can be calculated, using the example of the UK EQ-5D-3L value set.

View Article and Find Full Text PDF

Background: The objective of this study was to assess the content validity of the EQ-5D-5L and four bolt-ons: skin irritation, self-confidence, social relationships and sleep, for people with atopic dermatitis (AD) and chronic urticaria (CU).

Methods: Adults with AD or CU in the United Kingdom, with varying levels of severity, participated in either online or in-person semi-structured interviews. During the interviews, participants were first asked about the symptoms and impacts of their condition.

View Article and Find Full Text PDF

Background: Incarcerated people are at high risk of blood-borne virus infections, particularly HCV, and a priority population for elimination efforts. This national bio-behavioural survey evaluated blood-borne virus prevalence and HCV testing-and-treatment uptake amongst people in Australian prisons.

Methods: Randomly-selected participants from 23 representative prisons nationally were offered point-of-care testing for HIV and HCV (anti-HCV) antibodies, hepatitis B surface antigen (HBsAg), and HCV RNA (if anti-HCV positive).

View Article and Find Full Text PDF

Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants.

EBioMedicine

December 2024

Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. Electronic address:

Background: Current literature informs us that bivalent vaccines will generate a broader serum neutralizing antibody response to multiple SARS-CoV-2 variants, but studies on how this breadth relates to the memory B cell (MBC) and T cell responses are sparse. This study compared breadth of neutralising antibody, and memory B and T cell responses to monovalent or a bivalent ancestral/Omicron BA.1 COVID-19 booster vaccine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!